MedTrace Logo

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

NCT00673257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2020-04-14

Study results available
· View outcomes & findings →

Summary

This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

OTHER

pharmacological study

pharmacological studies

PROCEDURE

dual x-ray absorptimetry

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Stacey L. Berg, MD · Texas Children's Cancer Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-07-31
Completion
2020-03-31

Countries

  • United States
  • Australia
  • Canada
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673257 on ClinicalTrials.gov